InMode Ltd. (NASDAQ:INMD) Position Boosted by Harvey Capital Management Inc.

Harvey Capital Management Inc. increased its holdings in InMode Ltd. (NASDAQ:INMD) by 1.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,490 shares of the healthcare company’s stock after purchasing an additional 700 shares during the quarter. Harvey Capital Management Inc. owned 0.06% of InMode worth $860,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in INMD. Inspire Advisors LLC boosted its stake in shares of InMode by 45.5% during the 3rd quarter. Inspire Advisors LLC now owns 31,192 shares of the healthcare company’s stock worth $529,000 after acquiring an additional 9,759 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in InMode by 314.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after purchasing an additional 2,694 shares in the last quarter. GW Henssler & Associates Ltd. purchased a new position in shares of InMode in the third quarter worth approximately $177,000. EMC Capital Management raised its holdings in shares of InMode by 219.4% during the third quarter. EMC Capital Management now owns 13,319 shares of the healthcare company’s stock valued at $226,000 after acquiring an additional 9,149 shares during the period. Finally, Easterly Investment Partners LLC raised its holdings in shares of InMode by 26.6% during the third quarter. Easterly Investment Partners LLC now owns 121,589 shares of the healthcare company’s stock valued at $2,061,000 after acquiring an additional 25,579 shares during the period. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Stock Performance

INMD opened at $18.58 on Wednesday. InMode Ltd. has a twelve month low of $14.87 and a twelve month high of $26.80. The business has a 50 day moving average price of $17.34 and a 200 day moving average price of $17.21. The firm has a market cap of $1.29 billion, a P/E ratio of 7.91 and a beta of 2.13.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on INMD. BTIG Research assumed coverage on shares of InMode in a research report on Thursday, October 17th. They set a “buy” rating and a $25.00 price objective on the stock. Barclays upped their price target on InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 5th. Finally, Needham & Company LLC restated a “hold” rating on shares of InMode in a research report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $23.00.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.